<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127148</url>
  </required_header>
  <id_info>
    <org_study_id>GATLA 11-LLA Ph(-)-20 AYA</org_study_id>
    <nct_id>NCT05127148</nct_id>
  </id_info>
  <brief_title>RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL</brief_title>
  <official_title>Real-world Evidence of First-line Treatment With Pediatric-like Protocol for Adolescents and Young Adults Patients Diagnosed With Philadelphia-negative Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Argentino de Tratamiento de la Leucemia Aguda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Argentino de Tratamiento de la Leucemia Aguda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, observational real world clinical trial with prospective follow up&#xD;
      that will evaluate the treatment outcome of adolescent and young patients with ph-negative&#xD;
      acute lymphoblastic leukemia with first-line pediatric-like protocol in Argentina.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to gather real world evidence of treatment outcomes and&#xD;
      toxicities of AYA Ph-negative ALL patients in Argentina who receive pediatric-like treatment&#xD;
      in first line.&#xD;
&#xD;
      The study primary endpoints are to evaluate survival (event free survival and overall&#xD;
      survival) and toxicities of AYA Ph-negative ALL patients treating in first line with&#xD;
      pediatric-like protocol depending on risk category.&#xD;
&#xD;
      Secondary endpoints are to evaluate survival in patients who underwent allogeneic&#xD;
      transplantation in first remission, asparaginase toxicities, and assess central cerebrospinal&#xD;
      fluid by flow cytometry.&#xD;
&#xD;
      Every ALL patient diagnosed in our institutions will follow our guidelines with respect to&#xD;
      diagnosis procedures.&#xD;
&#xD;
      High-risk (HR) group was defined as presenting high risk cytogenetics/molecular findings and&#xD;
      depending on the response achieved at different time points: bad response to prednisone at&#xD;
      day 8, ≥ 10% blast in bone marrow on day 15, minimal residual disease (MRD) by flow cytometry&#xD;
      ≥0.1% at day 33 and ≥0.01% at day 78 in bone marrow. No-high risk group was defined as those&#xD;
      without any high-risk factor.&#xD;
&#xD;
      The chemotherapy regimen included pre-induction phase, induction (phase I and II),&#xD;
      consolidation, re-intensification, central nervous system (CNS) prophylaxis and maintenance&#xD;
      therapy or ASCT in first remission .&#xD;
&#xD;
      The initial pre-induction phase, where steroids were given for 7 days. Induction therapy,&#xD;
      phase IA consisted of weekly vincristine and daunorubicin for 4 weeks, L-Asparaginase for 8&#xD;
      doses or peg-asparaginase for 2 doses and prednisone continuously for 4 weeks. Phase IB&#xD;
      consisted cytarabine for 16 doses, cyclophosphamide for 1-2 doses and 6-mercaptopurine for 28&#xD;
      days.&#xD;
&#xD;
      The consolidation phase consisted of 4 doses of methotrexate and 6-mercaptopurine for 56 days&#xD;
      for Non-High Risk patients (M phase) and two cycles of three different blocks of high dose&#xD;
      multi chemotherapy for HR patients. Re-induction consisted in two phases similar to&#xD;
      induction. According to risk and response to treatment, patients will be candidates to&#xD;
      maintenance for 18 months or ASCT in first remission.&#xD;
&#xD;
      Minimal residual disease will be evaluated at least on day 33, 78, in consolidation and every&#xD;
      thee months during maintenance treatment or previous to ASCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>60 Months</target_duration>
  <primary_outcome>
    <measure>Evaluate event free survival of AYA Ph-negative ALL patients treating in first line depending on risk category.</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate event free survival of AYA Ph-negative ALL patients treating in first line with pediatric-like protocol depending on risk category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate overall survival of AYA Ph-negative ALL patients treating in first line depending on risk category.</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate overall survival of AYA Ph-negative ALL patients treating in first line with pediatric-like protocol depending on risk category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate toxicities of AYA Ph-negative ALL patients treating in first line depending on risk category.</measure>
    <time_frame>36 months</time_frame>
    <description>Evaluate toxicities of AYA Ph-negative ALL patients treating in first line with pediatric-like protocol depending on risk category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate survival in patients who underwent allogeneic transplantation in first remission</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate asparaginase toxicities.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess central cerebrospinal fluid involvement by flow cytometry.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Adult</condition>
  <arm_group>
    <arm_group_label>Adolescents and young adults Ph-negative ALL patients in first-line</arm_group_label>
    <description>Adolescents and young adults patients (18-40 years old) with recent diagnosis of Ph-negative acute lymphoblastic leukemia who receive argentinian pediatric-like treatment depending on risk category.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.</intervention_name>
    <description>Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.</description>
    <arm_group_label>Adolescents and young adults Ph-negative ALL patients in first-line</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All AYA (18-40 years old) with recent diagnosis of ph-negative ALL without previous&#xD;
        treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signature of the form consent for participation in the study&#xD;
&#xD;
          -  Ph-negative ALL diagnosis without previous treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ALL with mature B phenotype (sIg +) or with the cytogenetic alterations characteristic&#xD;
             of ALL mature B (t (8,14), t (2, 8), t (8, 22)).&#xD;
&#xD;
          -  Ph-positive ALL&#xD;
&#xD;
          -  Acute leukemias of ambiguous lineage (undifferentiated or mixed phenotype).&#xD;
&#xD;
          -  Patients with a history of coronary, valvular or hypertensive heart disease, that&#xD;
             contraindicate the use of anthracyclines.&#xD;
&#xD;
          -  Patients with chronic liver disease in the activity phase and / or Bilirubin&gt; 2 mg /&#xD;
             dl and / or transaminases 5 times the normal limit, not related to ALL.&#xD;
&#xD;
          -  Patients with severe chronic respiratory failure.&#xD;
&#xD;
          -  Renal failure and / or creatininemia&gt; 2 mg / dl not related to ALL.&#xD;
&#xD;
          -  Serious neurological disorders, not related to leukemic disease.&#xD;
&#xD;
          -  General condition affected (grades 3 and 4), not attributable to ALL.&#xD;
&#xD;
          -  Uncontrolled infection by HIV, HTLV-1, HBV, HCV.&#xD;
&#xD;
          -  Patient not a candidate for treatment based on the criteria of the treating physician.&#xD;
&#xD;
          -  Pregnant women will have to be evaluated by a multidisciplinary team and an ethics&#xD;
             committee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Maria Moirano, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Argentino de Tratamiento de la Leucemia Aguda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isolda Fernández, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Argentino de Tratamiento de la Leucemia Aguda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciana Ferrari, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Argentino de Tratamiento de la Leucemia Aguda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana Ferrari, Dr.</last_name>
    <phone>541148771000</phone>
    <email>lferrari@fundaleu.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Freigeiro</last_name>
    <phone>5491140470052</phone>
    <email>gatla.ar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FUNDALEU</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana Ferrari, Dr.</last_name>
      <phone>541148771000</phone>
      <email>lferrari@fundaleu.org.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Share study protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The data will become available on June 2021, and will remain available until the end of the clinical trial.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

